.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,144,571

« Back to Dashboard

Details for Patent: 9,144,571

Title:Muscarinic acetylcholine receptor antagonists
Abstract: Methods of using Muscarinic Acetylcholine Receptor Antagonists are provided.
Inventor(s): Laine; Dramane Ibrahim (King of Prussia, PA), Palovich; Michael R. (King of Prussia, PA), McCleland; Brent W. (King of Prussia, PA), Neipp; Christopher E. (King of Prussia, PA), Thomas; Sonia M. (King of Prussia, PA)
Assignee: Glaxo Group Limited (Brentford, Middlesex, GB)
Filing Date:May 08, 2015
Application Number:14/707,543
Claims:1. A method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human in need thereof, which comprises contacting the acetylcholine receptor with an effective amount of a compound of formula (I) ##STR00047## wherein: R1 is ##STR00048## R2 and R3 are independently selected from the group consisting of: ##STR00049## where F, G, H, K, and L are independently selected from the group consisting of hydrogen, halogen, --C1-4 alkyl, halosubstituted --C1-4 alkyl, hydroxyl substituted alkyl, and --C.sub.1-4 alkoxy; m is an integer having a value of 1 to 15; X, Y, Z, and W are independently selected from the group consisting of hydrogen and --C.sub.1-4 alkyl; X.sup.- is a pharmaceutically acceptable anion selected from the group consisting of chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate, and p-toluenesulfonate, and wherein the method of contacting the receptor is via inhalation by the mouth or nose of said human.

2. A method according to claim 1 wherein X, Y, Z, and W are hydrogen.

3. The method according to claim 2, wherein the compound is: 1-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]-4-[hydroxy(diphenyl)m- ethyl]-1-azo-niabicyclo[2.2.2]octane bromide; or 1-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propyl]-4.about.[hydroxy(dip- henyl)methyl]-1-azo-niabicyclo[2.2.2]octane bromide.

4. A method of inhibiting the binding of acetylcholine to a M.sub.3 muscarinic acetylcholine receptor in a human in need thereof, which comprises contacting the M.sub.3 muscarinic acetylcholine receptor with an effective amount of a compound of formula (I) ##STR00050## wherein: R1 is selected from the group consisting of --C.sub.1-15 alkyl, halosubstituted --C.sub.1-15 alkyl, --C.sub.1-15alkyl cycloalkyl, --C.sub.2-15 alkenyl, hydroxyl substituted --C.sub.1-15 alkyl, --C.sub.1-15 alkylaryl, --C.sub.1-15 alkyl heteroaryl, --(CR7R7)qNRaRa, --(CR7R7)qNC(O)Ra, --(CR7R7)qNC(O)NRaRa, --(CR7R7)qC(O)Ra, --(CR7R7)qOC(O)Ra, --(CR7R7)qORc, and --(CR7R7)qNS(O).sub.2Ra; R2 and R3 are independently selected from the group consisting of: ##STR00051## wherein F, G, H, K, and L are independently selected from the group consisting of hydrogen, halogen, --C.sub.1-4 alkyl, halosubstituted --C.sub.1-4 alkyl, hydroxyl substituted alkyl, and --C.sub.1-4 alkoxy; R7 is selected from a group consisting of hydrogen, --C.sub.1-4 alkyl, halosubstituted --C.sub.1-4 alkyl, and hydroxysubstituted --C.sub.1-4 alkyl; Ra is selected from the group consisting of hydrogen, --C.sub.1-15 alkyl, --C.sub.1-15 alkoxy, aryl, --C.sub.1-15 alkyl aryl, heteroaryl, --C.sub.1-15 alkyl heteroaryl, heterocyclic, and a --C.sub.1-15 alkyl heterocyclic moiety, all of which moieties excluding hydrogen may be optionally substituted; Rc is selected from a group consisting of hydrogen, --C.sub.1-15 alkyl, --C.sub.1-15 alkoxy, heterocyclic, and a --C.sub.1-15 alkyl heterocyclic moiety, all of which moieties, excluding hydrogen may be optionally substituted; q is 0 or an integer having a value of 1 to 15; X.sup.- is a pharmaceutically acceptable anion selected from the group consisting of chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate, and p-toluenesulfonate, and wherein the method of contacting the receptor is via inhalation by the mouth or nose of said human.

5. The method according to claim 4 wherein R1 is --C.sub.1-15 alkyl.

6. The method according to claim 5, wherein the compound is: 1-ethyl-4-[hydroxy(diphenyl)methyl]-1-azoniabicyclo[2.2.2]octane bromide; 4-[hydroxy(diphenyl)methyl]-1-nonyl-1-azoniabicyclo[2.2.2]octane bromide; 4-[hydroxy(diphenyl)methyl]-1-methyl-1-azoniabicyclo[2.2.2]octane bromide; 1-butyl-4-[hydroxy(diphenyl)methyl]-1-azoniabicyclo[2.2.2]octane bromide; 1-hexyl-4-[hydroxy(diphenyl)methyl]-1-azoniabicyclo[2.2.2]octane bromide; 4-[hydroxy(diphenyl)methyl]-1-propyl-1-azoniabicyclo[2.2.2]octan- e bromide; or 1-butyl-4-[hydroxy(di.about.3-thienyl)methyl]-1-azoniabicyclo[2.2.2]octan- e bromide.

7. The method according to claim 4 wherein R1 is halosubstituted --C.sub.1-15 alkyl.

8. The method according to claim 7, wherein the compound is: 1-(3-bromopropyl)-4-hydroxy(diphenyl)methyl]-1-azoniabicyclo[2.2.2]octane bromide.

9. The method according to claim 4 wherein R1 is --C.sub.1-15 alkyl cycloalkyl.

10. The method according to claim 9, wherein the compound is: 1-(cyclopropylmethyl)-4-[hydroxy(diphenyl)methyl]-1-azoniabicyclo[2.2.2]o- ctane bromide.

11. The method according to claim 4 wherein R1 is --C2-15 alkenyl.

12. The method according to claim 11, wherein the compound is: 4-[hydroxy(diphenyl)methyl]-1-(4-penten-1-yl)-1-azoniabicyclo[2.2.2]octan- e bromide; 4-[hydroxy(diphenyl)methyl]-1-(2-propen-1-yl)-1-azoniabicyclo[2- .2.2]octane bromide; or 1-(5-hexen-1-yl)-4-[hydroxy(diphenyl)methyl]-1-azoniabicyclo[2.2.2]octane bromide.

13. The method according to claim 4 wherein R1 is hydroxyl substituted --C.sub.1-15 alkyl.

14. The method according to claim 13, wherein the compound is: 4-[hydroxy(diphenyl)methyl]-1-(2-hydroxyethyl)-1-azoniabicyclo[2.2.2]octa- ne bromide.

15. The method according to claim 4 wherein R1 is --C.sub.1-15 alkyl aryl.

16. The method according to claim 15, wherein the compound is: 4-[hydroxy(diphenyl)methyl]-1-(2-phenylethyl)-1-azoniabicyclo[2.2.2]octan- e bromide; 4-[hydroxy(diphenyl)methyl]-1-(3-phenylpropyl)-1-azoniabicyclo[- 2.2.2]octane bromide; 4-[hydroxy(diphenyl)methyl]-1-(1-phenylmethyl)-1-azoniabicyclo[2.2.2]octa- ne bromide 4-[hydroxy(diphenyl)methyl]-1-(2-naphthylmethyl)-1-azoniabicycl- o[2.2.2]octane bromide; 4-[hydroxy(di-2-thienyl)methyl]-1-(2-phenylethyl)-1-azoniabicyclo[2.2.2]o- ctane bromide; or 4-[hydroxy(di-2-thienyl)methyl]-1-(3-phenylpropyl)-1-azoniabicyclo[2.2.2]- octane bromide.

17. The method according to claim 4 wherein R1 is --C.sub.1-15 alkyl heteroaryl.

18. The method according to claim 17, wherein the compound is: 4-[hydroxy(diphenyl)methyl]-1-[2-(1H-indol-3-yl)ethyl]-naphthylmethyl)-1-- azoniabicyclo[2.2.2]octane bromide.

19. The method according to claim 4 wherein R1 is --(CR7R7)qNRaRa.

20. The method according to claim 19, wherein the compound is: 1-(2-aminoethyl)-1-azoniabicyclo[2.2.2]oct-4-yl](diphenyl)methanolate trifluoroacetate.

21. The method according to claim 4 wherein R1 is --(CR7R7)qC(O)Ra.

22. The method according to claim 21, wherein the compound is: 4-[hydroxy(diphenyl)methyl]-1-(2-oxo-2-phenylethyl)-1-azoniabicyclo[2.2.2- ]octane-bromide; 1-[2-(1-benzofuran-2-yl)-2-oxoethyl]-4-[hydroxy(diphenyl)methyl]-1-azonia- bicyclo[2.2.2]-octane bromide; 1-[2-([1,1'-biphenyl]-4-yl)-2-oxoethyl]-4-[hydroxy(diphenyl)methyl]-1-azo- niabicyclo[2.2.2]-octane bromide; or 1-[2-(naphthalen-2-yl)-2-oxoethyl]-4-[hydroxy(diphenyl)methyl]-1-azoniabi- cyclo[2.2.2]-octane bromide.

23. The method according to claim 4 wherein R1 is --(CR7R7)qOC(O)Ra.

24. The method according to claim 23, wherein the compound is: 1-[2-(benzoyloxy)ethyl]-4-[hydroxy(diphenyl)methyl]-1-azoniabicyclo[2.2.2- ]octane-bromide.

25. The method according to claim 4 wherein R1 is --(CR7R7)qORc.

26. The method according to claim 25, wherein the compound is: 4-[hydroxy(diphenyl)methyl]-1-[2-(methyloxy)ethyl]-1-azoniabicyclo[2.2.2]- octane bromide; or 4-[hydroxy(diphenyl)methyl]-1-[3-(methyloxy)propyl]-1-azoniabicyclo[2.2.2- ]octane bromide.

27. The method according to claim 1, wherein said compound is presented as a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

28. The method according to claim 4, wherein said compound is presented as a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

29. A method according to claim 1 wherein the binding of the acetylcholine receptor is useful in the treatment of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema or allergic rhinitis.

30. A method according to claim 4 wherein the binding of the M3 muscarinic acetylcholine receptor is useful in the treatment of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema or allergic rhinitis.

31. A method of claim 27, wherein the composition is administrated by inhalation via a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler, or a metered dose inhaler.

32. A method of claim 28, wherein the composition is administrated by inhalation via a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler, or a metered dose inhaler.

33. A method according to claim 31 wherein said pharmaceutical composition comprises a dry powder composition.

34. A method according to claim 32 wherein said pharmaceutical composition comprises a dry powder composition.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc